Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 11, 2007 - Issue 10
Submit an article Journal homepage
132
Views
20
CrossRef citations to date
0
Altmetric
Review

Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease

Mario Cazzola Associate Professor of Respiratory Medicine, Universitá di Roma ‘Tor Vergata’, Dipartimento di Medicina Interna, Via Montpellier 1, 00133 Roma, Italy +39 06 72596621; +39 06 72596621; [email protected]
, MD,
Chiara Ciaprini Postgraduate Student in Respiratory Medicine, University of Rome ‘Tor Vergata’, Department of Internal Medicine, Unit of Respiratory Diseases, Rome, Italy
, MD,
Clive P Page Professor of Pharmacology and Director, Sackler Institute of Pulmonary Pharmacology, Division of Pharmaceutical SciencesKing's College London, UK
, PhD &
Maria G Matera Aggregate Professor of Pharmacology, Second University of Naples, Department of Experimental Medicine, Unit of Pharmacology and Toxicology, Naples, Italy
, MD, PhD
Pages 1273-1286 | Published online: 02 Oct 2007

Bibliography

  • AGUSTI A: Chronic obstructive pulmonary disease: a systemic disease. Proc. Am. Thorac. Soc. (2006) 3:478-481.
  • GAN WQ, MAN SF, SENTHILSELVAN A, SIN DD: Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax (2004) 59:574-580.
  • WOUTERS EF: Chronic obstructive pulmonary disease. 5. Systemic effects of COPD. Thorax (2002) 57:1067-1070.
  • AGUSTI AG, NOGUERA A, SAULEDA J, SALA E, PONS J, BUSQUETS X: Systemic effects of chronic obstructive pulmonary disease. Eur. Respir. J. (2003) 21:347-360.
  • FOGARTY AW, JONES S, BRITTON JR, LEWIS SA, MCKEEVER TM: Systemic inflammation and decline in lung function in a general population: a prospective study. Thorax (2007) 62:515-520.
  • THYAGARAJAN B, JACOBS DR, APOSTOL GG, SMITH LJ, LEWIS CE, WILLIAMS OD: Plasma fibrinogen and lung function: the CARDIA study. Int. J. Epidemiol. (2006) 35:1001-1008.
  • DAHL M, VESTBO J, LANGE P, BOJESEN SE, TYBJAERG-HANSEN A, NORDESTGAARD BG: C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2007) 175:250-255.
  • CELLI BR, MACNEE W, AGUSTI AG et al.: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J. (2004) 23:932-946.
  • VAN EEDEN SF, HOGG JC: The response of human bone marrow to chronic cigarette smoking. Eur. Respir. J. (2000) 15:915-921.
  • NOGUERA A, BATLE S, MIRALLES C et al.: Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax (2001) 56:432-437.
  • GUSTAFSSON A, ASMAN B, BERGSTROM K: Cigarette smoking as an aggravating factor in inflammatory tissue-destructive diseases. Increase in TNF-α priming of peripheral neutrophils measured as generation of oxygen radicals. Int. J. Clin. Lab. Res. (2000) 30:187-190.
  • GAN WQ, MAN SF, SIN DD: The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest (2005) 127:558-664.
  • ANDELID K, BAKE B, RAK S, LINDEN A, ROSENGREN A, EKBERG-JANSSON A: Myeloperoxidase as a marker of increasing systemic inflammation in smokers without severe airway symptoms. Respir. Med. (2007) 101:888-895.
  • TØNNESEN P, CARROZZI L, FAGERSTROM KO et al.: Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur. Respir. J. (2007) 29:390-417.
  • RUTGERS SR, POSTMA DS, TEN HACKEN NH et al.: Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax (2000) 55:12-18.
  • TURATO G, DI STEFANO A, MAESTRELLI P et al.: Effect of smoking cessation on airway inflammation in chronic bronchitis. Am. J. Respir. Crit. Care Med. (1995) 152:1262-1267.
  • PATEL SA, CHOI AM, ZHANG Y et al.: Systemic biomarker pattern in different chronic obstructive pulmonary disease phenotypes independent of smoking status. Proc. Am. Thorac. Soc. (2006) 3:551 (Abstract).
  • VASSILAKOPOULOS T, ROUSSOS C, ZAKYNTHINOS S: The immune response to resistive breathing. Eur. Respir. J. (2004) 24:1033-1043.
  • VASSILAKOPOULOS T, ROUSSOS C, ZAKYNTHINOS S: Is loaded breathing an inflammatory stimulus? Curr. Opin. Crit. Care (2005) 11:1-9.
  • XU X, ZHOU J, YANG Q, FANG L, XIE Q, SHEN Y: An in vitro rat diaphragmatic fatigue model induced by combined hypoxic and hypercapnic acidosis and the effect of salmeterol. Pharmacol. Res. (2006) 3:171-176.
  • CARBO N, LOPEZ-SORIANO J, TARRAGO T et al.: Comparative effects of β2-adrenergic agonists on muscle waste associated with tumour growth. Cancer Lett. (1997) 115:113-118.
  • HARCOURT LJ, SCHERTZER JD, RYALL JG, LYNCH GS: Low dose formoterol administration improves muscle function in dystrophic mdx mice without increasing fatigue. Neuromuscul. Disord. (2007) 17:47-55.
  • VAN DER HEIJDEN HF, HEUNKS LM, FOLGERING H, VAN HERWAARDEN CL, DEKHUIJZEN PN: β2-Adrenoceptor agonists reduce the decline of rat diaphragm twitch force during severe hypoxia. Am. J. Physiol. (1999) 276:L474-L480.
  • KISSEL JT, MCDERMOTT MP, MENDELL JR et al.: Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. Neurology (2001) 57:1434-1440.
  • KIM YS, SAINZ RD: β-Adrenergic agonists and hypertrophy of skeletal muscles. Life Sci. (1992) 50:397-407.
  • RAJAB P, FOX J, RIAZ S, TOMLINSON D, BALL D, GREENHAFF PL: Skeletal muscle myosin heavy chain isoforms and energy metabolism after clenbuterol treatment in the rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2000) 279:R1076-R1081.
  • RYALL JG, SILLENCE MN, LYNCH GS: Systemic administration of β2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses. Br. J. Pharmacol. (2006) 147:587-595.
  • MOLENAAR P, CHEN L, PARSONAGE WA: Cardiac implications for the use of β2-adrenoceptor agonists for the management of muscle wasting. Br. J. Pharmacol. (2006) 147:583-586.
  • CAZZOLA M, MATERA MG, DONNER CF: Inhaled β2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs (2005) 65:1595-1610.
  • BARNES PJ: Effect of β-agonists on inflammatory cells. J. Allergy Clin. Immunol. (1999) 104:S10-S17.
  • JOHNSON M, RENNARD S: Alternative mechanisms for long-acting β2-adrenergic agonists in COPD. Chest (2001) 120:258-270.
  • BOWDEN JJ, SULAKVELIDZE I, MCDONALD DM: Inhibition of neutrophil and eosinophil adhesion to venules of rat trachea by β2-adrenergic agonist formoterol. J. Appl. Physiol. (1994) 77:397-405.
  • YOSHIMURA T, KURITA C, NAGAO T et al.: Inhibition of TNF-α and interleukin-1-β production by β-adrenoceptor agonists from lipopolysaccharide-stimulated human peripheral blood mononuclear cells. Pharmacology (1997) 4:144-152.
  • OTTONELLO L, MORONE P, DAPINO P, DALLEGRI F: Inhibitory effect of salmeterol on the respiratory burst of adherent human neutrophils. Clin. Exp. Immunol. (1996) 106:97-102.
  • KAWASHIMA K, FUJII T: The lymphocytic cholinergic system and its biological function. Life Sci. (2003) 72:2101-2109.
  • PAVLOV VA, TRACEY KJ: Controlling inflammation: the cholinergic anti-inflammatory pathway. Biochem. Soc. Trans. (2006) 34:1037-1040.
  • WESSLER I, KILBINGER H, BITTINGER F, UNGER R, KIRKPATRICK CJ: The non-neuronal cholinergic system in humans: expression, function and pathophysiology. Life Sci. (2003) 72:2055-2061.
  • BARNES PJ, STOCKLEY RA: COPD: current therapeutic interventions and future approaches. Eur. Respir. J. (2005) 25:1084-1106.
  • KOYAMA S, RENNARD SI, ROBBINS RA: Acetylcholine stimulates bronchial epithelial cells to release neutrophil and monocyte chemotactic activity. Am. J. Physiol. (1992) 262:L466-L471.
  • KOYAMA S, SATO E, NOMURA H, KUBO K, NAGAI S, IZUMI T: Acetylcholine and substance P stimulate bronchial epithelial cells to release eosinophil chemotactic activity. J. Appl. Physiol. (1998) 84:1528-1534.
  • KLAPPROTH H, RACKE K, WESSLER I: Acetylcholine and nicotine stimulate the release of granulocyte-macrophage colony stimulating factor from cultured human bronchial epithelial cells. Naunyn Schmiedebergs Arch. Pharmacol. (1998) 357:472-475.
  • PROSKOCIL BJ, SEKHON HS, JIA Y et al.: Acetylcholine is an autocrine or paracrine hormone synthesized and secreted by airway bronchial epithelial cells. Endocrinology (2004) 145:2498-2506.
  • GOSENS R, ZAAGSMA J, MEURS H, HALAYKO AJ: Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir. Res. (2006) 7:73.
  • CELLI B, ZUWALLACK R, WANG S, KESTEN S: Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest (2003) 124:1743-1748.
  • O'DONNELL DE, FLÜGE T, GERKEN F et al.: Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in patients with COPD. Eur. Respir. J. (2004) 23:832-840.
  • FERGUSON GT: Why does the lung hyperinflate? Proc. Am. Thorac. Soc. (2006) 3:176-179.
  • SALPETER SR, BUCKLEY NS, SALPETER EE: Meta-analysis: anticholinergics, but not β-agonists, reduce severe exacerbations and respiratory mortality in COPD. J. Gen. Intern. Med. (2006) 21:1011-1019.
  • BARNES PJ: Theophylline for COPD. Thorax (2006) 61:742-744.
  • ITO K, LIM S, CARAMORI G et al.: A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease gene expression. Proc. Natl. Acad. Sci. USA (2002) 99:8921-8926.
  • BARNES PJ: Targeting histone deacetylase 2 in chronic obstructive pulmonary disease treatment. Expert Opin. Ther. Targets (2005) 9:1111-1121.
  • BARNES PJ: Reduced histone deacetylase in COPD: clinical implications. Chest (2006) 129:151-155.
  • COSIO BG, TSAPROUNI L, ITO K, JAZRAWI E, ADCOCK IM, BARNES PJ: Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J. Exp. Med. (2004) 200:689-695.
  • WASSERMAN SI: The mast cell and theophylline in asthma. Am. J. Med. (1985) 20:22-25.
  • PAUWELS RA: New aspects of the therapeutic potential of theophylline in asthma. J. Allergy Clin. Immunol. (1989) 83:548-553.
  • KRAFT M, TORVIK JA, TRUDEAU JB, WENZEL SE, MARTIN RJ: Theophylline: potential antiinflammatory effects in nocturnal asthma. J. Allergy Clin. Immunol. (1996) 97:1242-1246.
  • SOSLAU G, BRODSKY I, PARKER J: Occupancy of P2 purinoceptors with unique properties modulates the function of human platelets. Biochim. Biophys. Acta (1993) 1177:199-207.
  • KOBAYASHI M, NASUHARA Y, BETSUYAKU T et al.: Effect of low-dose theophylline on airway inflammation in COPD. Respirology (2004) 9:249-254.
  • IIBOSHI H, ASHITANI J, KATOH S et al.: Long-term treatment with theophylline reduces neutrophils, interleukin-8 and TNF-α in the sputum of patients with chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. (2007) 20:46-51.
  • GAN WQ, MAN SF, SIN DD: Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulm. Med. (2005) 5:3.
  • SIN DD, LACY P, YORK E, MAN SF: Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2004) 170:760-765.
  • PINTO-PLATA VM, MULLEROVA H, TOSO JF et al.: C-reactive protein in patients with COPD, control smokers, and nonsmokers. Thorax (2006) 61:23-28.
  • VAN SNICK J: Interleukin-6: an overview. Annu. Rev. Immunol. (1990) 8:253-278.
  • LIBBY P, RIDKER PM: Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am. J. Med. (2004) 116:S9-S16.
  • DANESH J, WHEELER JG, HIRSCHFIELD GM et al.: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. (2004) 350:1387-1397.
  • SIN DD, MAN SF: Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation (2003) 107:1514-1519.
  • LÖFDAHL C-G, POSTMA DS, PRIDE NB, BOE J, THORÉN A: Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur. Respir. J. (2007) 29(6):1115-1119.
  • HUIART L, ERNST P, RANOUIL X, SUISSA S: Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur. Respir. J. (2005) 25:634-639.
  • SIN DD, WU L, ANDERSON JA et al.: Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax (2005) 60:992-997.
  • CALVERLEY PM, ANDERSON JA, CELLI B et al.: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. (2007) 356:775-789.
  • WEI L, MACDONALD TM, WALKER BR: Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann. Intern. Med. (2004) 141:764-770.
  • BARNES NC, QIU YS, PAVORD ID et al.: Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. (2006) 173:736-743.
  • PERNG DW, WU CC, SU KC, LEE YC, PERNG RP, TAO CW: Inhaled fluticasone and salmeterol suppress eosinophilic airway inflammation in chronic obstructive pulmonary disease: relations with lung function and bronchodilator reversibility. Lung (2006) 184:217-222.
  • SIN DD, MAN SF, MARCINIUK DD et al.: Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. BMC Pulm. Med. (2006) 6:3.
  • SORIANO JB, VESTBO J, PRIDE NB, KIRI V, MADEN C, MAIER WC: Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur. Respir. J. (2002) 20:819-825.
  • BURNEY P, SUISSA S, SORIANO JB et al.: The pharmacoepidemiology of COPD: recent advances and methodological discussion. Eur. Respir. J. (2003) 22(Suppl. 43):S1-S44.
  • MATERA MG, CAZZOLA M: New anti-inflammatory approaches in COPD. Drug Discov. Today Ther. Strat. (2004) 1:335-343.
  • CULPITT SV, ROGERS DF, SHAH P et al.: Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2003) 167:24-31.
  • BARNES PJ: New molecular targets for the treatment of neutrophilic diseases. J. Allergy Clin. Immunol. (2007) 119:1055-1062.
  • DONNELLY LE, BARNES PJ: Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends Pharmacol. Sci. (2006) 27:546-453.
  • MAHLER DA, HUANG S, TABRIZI M, BELL GM: Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest (2004) 126:926-934.
  • BUKHTIYAROVA M, NORTHROP K, CHAI X, CASPER D, KARPUSAS M, SPRINGMAN E: Improved expression, purification, and crystallization of p38a MAP kinase. Protein Exp. Purif. (2004) 37:154-161.
  • ZHANG J, SHEN B, LIN A: Novel strategies for inhibition of the p38 MAPK pathway. Trends Pharmacol. Sci. (2007) 28:286-295.
  • KUMAR S, BOEHM J, LEE JC: p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat. Rev. Drug Discov. (2003) 2:717-726.
  • VAN DER VAART H, KOETER GH, POSTMA DS, KAUFFMAN HF, TEN HACKEN NH: First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2005) 172:465-469.
  • RENNARD SI, FOGARTY C, KELSEN S et al.: The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2007) 175:926-934.
  • BOSWELL-SMITH V, CAZZOLA M, PAGE CP: Are phosphodiesterase 4 inhibitors just more theophylline? J. Allergy Clin. Immunol. (2006) 117:1237-1243.
  • SOUNESS JE, ALDOUS D, SARGENT C: Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology (2000) 47:127-162.
  • RABE KF, BATEMAN ED, O'DONNELL D, WITTE S, BREDENBROKER D, BETHKE TD: Roflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2005) 366:563-571.
  • RENNARD SI, SCHACHTER N, STREK M, RICKARD K, AMIT O: Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest (2006) 129:56-66.
  • OUAGUED M, MARTIN-CHOULY CA, BRINCHAULT G et al.: The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-α production in whole blood from COPD patients. Pulm. Pharmacol. Ther. (2005) 18:49-54.
  • MCCLUSKIE K, KLEIN U, LINNEVERS C et al.: Phosphodiesterase type 4 inhibitors cause proinflammatory effects in vivo. J. Pharmacol. Exp. Ther. (2006) 319:468-476.
  • GIEMBYCZ MA: Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Curr. Opin. Pharmacol. (2005) 5:238-244.
  • TYRRELL DJ, HORNE AP, HOLME KR, PREUSS JM, PAGE CP: Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv. Pharmacol. (1999) 46:151-208.
  • LEVER R, PAGE CP: Novel drug development opportunities for heparin. Nat. Rev. Drug Discov. (2002) 1:140-148.
  • PAGE CP: One explanation of the asthma paradox: inhibition of natural anti-inflammatory mechanism by β2-agonists. Lancet (1991) 337:717-720.
  • WALSH RL, DILLON TJ, SCICCHITANO R, MCLENNAN G: Heparin and heparan sulphate are inhibitors of human leucocyte elastase. Clin. Sci. (1991) 81:341-346.
  • BROWN RA, LEVER R, JONES NA, PAGE CP: Effects of heparin and related molecules upon neutrophil aggregation and elastase release in vitro. Br. J. Pharmacol. (2003) 139:845-853.
  • LEDOUX D, MERCIRIS D, BARRITAULT D, CARUELLE JP: Heparin-like dextran derivatives as well as glycosaminoglycans inhibit the enzymatic activity of human cathepsin G. FEBS Lett. (2003) 537:23-29.
  • LEVER R, HOULT JR, PAGE CP: The effects of heparin and related molecules upon the adhesion of polymorphonuclear leukocytes to vascular endothelium in vitro. Br. J. Pharmacol. (2000) 129:533-540.
  • JONES H, PAUL W, PAGE CP: The effects of heparin and related molecules on vascular permeability and neutrophil accumulation in rabbit skin. Br. J. Pharmacol. (2002) 135:469-479.
  • BROWN RA, ALLEGRA L, MATERA MG, PAGE CP, CAZZOLA M: Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination. Pulm. Pharmacol. Ther. (2006) 19:419-424.
  • FRYER A, HUANG YC, RAO G et al.: Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung. J. Pharmacol. Exp. Ther. (1997) 282:208-219.
  • BAVINGTON CD, LEVER R, MULLOY B et al.: Anti-adhesive glycoproteins in echinoderm mucus secretions. Comp. Biochem. Physiol. B Biochem. Mol. Biol. (2004) 139:607-617.
  • RABINOVICH RA, ARDITE E, TROOSTERS T et al.: Reduced muscle redox capacity after endurance training in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2001) 164:1114-1118.
  • SAEY D, MICHAUD A, COUILLARD A et al.: Exercise-induced quadriceps oxidative stress and peripheral muscle dysfunction in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2003) 167:1664-1669.
  • AGUSTI AG: COPD, a multicomponent disease: implications for management. Respir. Med. (2005) 99:670-682.
  • KIRKHAM P, RAHMAN I: Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy. Pharmacol. Ther. (2006) 111:476-494.
  • SADOWSKA AM, MANUEL-Y-KEENOY B, DE BACKER WA: Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. Pulm. Pharmacol. Ther. (2007) 20:9-22.
  • DAVIS WB, PACHT ER: Extracellular antioxidant defenses. In: The Lung: Scientific Foundations (2nd Edition). Crystal RG, West JB, Weibel ER, Barnes PJ (Eds), Philadelphia, Lippincott-Raven (1997):2271-2278.
  • DECRAMER M, RUTTEN-VAN MOLKEN M, DEKHUIJZEN PN et al.: Effects of NAC on outcome of COPD. The bronchitis randomized on NAC cost-utility study (BRONCHUS). Lancet (2005) 365:1552-1560.
  • VAN HELVOORT HA, HEIJDRA YF, HEUNKS LM et al.: Supplemental oxygen prevents exercise-induced oxidative stress in muscle-wasted patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2006) 173:1122-1129.
  • LAROSA JC, HE J, VUPPUTURI S: Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials. JAMA (1999) 282:2340-2346.
  • RIDKER PM, CANNON CP, MORROW D et al.: C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. (2005) 352:20-28.
  • FERRO D, PARROTTO S, BASILI S, ALESSANDRI C, VIOLI F: Simvastatin inhibits the monocyte expression of proinflammatory cytokinesin patients with hypercholesterolemia. J. Am. Coll. Cardiol. (2000) 36:427-431.
  • HEINRICH PC, CASTELL JV, ANDUS T: Interleukin-6 and the acute phase response. Biochem. J. (1990) 265:621-636.
  • HOTHERSALL E, MCSHARRY C, THOMSON NC: Potential therapeutic role for statins in respiratory disease. Thorax (2006) 61:729-734.
  • JACOBSON JR, BARNARD JW, GRIGORYEV DN, MA SF, TUDER RM, GARCIA JG: Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. (2005) 288:L1026-L1032.
  • LEE JH, LEE DS, KIM EK et al.: Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am. J. Respir. Crit. Care Med. (2005) 172:987-993.
  • LEE SD, LEE JH, KIM EK, CHOI KH, OH YM, SHIM TS: Effects of simvastatin on cigarette smoking-induced structural and functional changes in rat lungs. Chest (2005) 128:S574 (Abstract).
  • TAKAHASHI S, NAKAMURA H, FURUUCHI M et al.: Simvastatin suppresses the development of elastase-induced emphysema in mice (abstract). Proc. Am. Thor. Soc. (2005) 2:A135 (Abstract).
  • YOUNIS WG, CHBEIR EA, DAHER NN, DERNAIKA TA, KINASEWITZ GT, KEDDISSI JI: Statins protect smokers from lung disease. Chest (2006) 130:S180 (Abstract).
  • ALEXEEFF SE, LITONJUA AA, SPARROW D, VOKONAS PS, SCHWARTZ J: Statin use reduces decline in lung function: VA normative anging study. Am. J. Respir. Crit. Care Med. (2007) [Epub ahead of print].
  • MORIMOTO K, JANSSEN WJ, FESSLER MB et al.: Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J. Immunol. (2006) 176:7657-7665.
  • HENSON PM, BRATTON DL, FADOK VA: Apoptotic cell removal. Curr. Biol. (2001) 11:R795-R805.
  • ODAKA C, MIZUOCHI T, YANG J, DING A: Murine macrophages produce secretory leukocyte protease inhibitor during clearance of apoptotic cells: implications for resolution of the inflammatory response. J. Immunol. (2003) 171:1507-1514.
  • MORIMOTO K, AMANO H, SONODA F et al.: Alveolar macrophages that phagocytose apoptotic neutrophils produce hepatocyte growth factor during bacterial pneumonia in mice. Am. J. Respir. Cell Mol. Biol. (2001) 24:608-615.
  • GOLPON HA, FADOK VA, TARASEVICIENE-STEWART L et al.: Life after corpse engulfment: phagocytosis of apoptotic cells leads to VEGF secretion and cell growth. FASEB J. (2004) 18:1716-1718.
  • MANCINI GB, ETMINAN M, ZHANG B, LEVESQUE LE, FITZGERALD JM, BROPHY JM: Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J. Am. Coll. Cardiol. (2006) 47:2554-2560.
  • SOYSETH V, BREKKE PH, SMITH P, OMLAND T: Statin use is associated with reduced mortality in chronic obstructive pulmonary disease. Eur. Respir. J. (2007) 29:279-283.
  • FROST FJ, PETERSEN H, TOLLESTRUP K, SKIPPER B: Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest (2007) 131:1006-1012.
  • VIERECK V, GRUNDKER C, BLASCHKE S et al.: Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts. J. Cell. Biochem. (2005) 96:1244-1253.
  • FERDER L, INSERRA F, MARTINEZ-MALDONADO M: Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress. Curr. Hypertens. Rep. (2006) 8:191-198.
  • KANAZAWA H, HIRATA K, YOSHIKAWA J: Effects of captopril administration on pulmonary hemodynamics and tissue oxygenation during exercise in ACE gene subtypes in COPD patients: a preliminary study. Thorax (2003) 58:629-631.
  • ANKER SD, NEGASSA A, COATS AJ et al.: Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet (2003) 361:1077-1083.
  • SHOUP R, DALSKY G, WARNER S et al.: Body composition and health-related quality of life in patients with obstructive airways disease. Eur. Respir. J. (1997) 10:1576-1580.
  • POEHLMAN ET, SCHEFFERS J, GOTTLIEB SS, FISHER ML, VAITEKEVICIUS P: Increased resting metabolic rate in patients with congestive heart failure. Ann. Intern. Med. (1994) 121:860-862.
  • ANKER SD, SWAN JW, VOLTERRANI M et al.: The influence of muscle mass, strength, fatiguability, and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. Eur. Heart J. (1997) 18:259-269.
  • DOEHNER W, RAUCHHAUS M, FLOREA VG et al.: Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance. Am. Heart J. (2001) 141:792-799.
  • HORNIG B, ARAKAWA N, DREXLER H: Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure. Eur. Heart J. (1998) 19(Suppl. G):G48-G53.
  • SWEDBERG K, ENEROTH P, KJEKSHUS J, WILHELMSEN L: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS trial study group. Circulation (1990) 82:1730-1736.
  • FRANCIS GS, COHN JN, JOHNSON G, RECTOR TS, GOLDMAN S, SIMON A: Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. Circulation (1993) 87(6 Suppl.):VI40-VI48.
  • ANDREAS S, HERRMANN-LINGEN C, RAUPACH T et al.: Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial. Eur. Respir. J. (2006) 27:972-979.
  • REMELS AH, SCHRAUWEN P, BROEKHUIZEN R et al.: Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD. Eur. Respir. J. (2007) 30:245-252.
  • HARRIS SG, PHIPPS RP: Induction of apoptosis in mouse T cells upon peroxisome proliferator-activated receptor γ (PPAR-γ) binding. Adv. Exp. Med. Biol. (2002) 507:421-425.
  • PATEL HJ, BELVISI MG, BISHOP-BAILEY D, YACOUB MH, MITCHELL JA: Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy. J. Immunol. (2003) 170:2663-2669.
  • BIRRELL MA, PATEL HJ, MCCLUSKIE K et al.: PPAR-γ agonists as therapy for diseases involving airway neutrophilia. Eur. Respir. J. (2004) 24:18-23.
  • SPEARS M, MCSHARRY C, THOMSON NC: Peroxisome proliferator-activated receptor-γ agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease. Clin. Exp. Allergy (2006) 36:1494-1504.
  • PFUTZNER A, SCHNEIDER CA, FORST T: Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. Expert. Rev. Cardiovasc. Ther. (2006) 4:445-459.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.